MCL Literature Feed

A novel SRC-3 inhibitor, SI-10, demonstrates preclinical efficacy in ibrutinib-resistant MCL models, identifying SRC-3 as a potential therapeutic target to overcome BTKi resistance.

This systematic review of real-world data supports positioning covalent BTKis as second-line therapy for relapsed/refractory MCL, followed by CAR-T cells for patients relapsing after BTKi treatment.

This retrospective review of 14 Moroccan patients describes real-world MCL clinical features and treatment patterns, providing rare epidemiological data from North Africa.

This review details the pathophysiology and management of CAR-T toxicities like CRS and ICANS, providing essential guidance for clinicians treating relapsed/refractory MCL patients with this therapy.

This review identifies the lncRNA ROR1-AS1 as a pro-oncogenic factor in mantle cell lymphoma, suggesting it may serve as a novel biomarker or therapeutic target.

This Mendelian randomization study suggests potential causal links between socioeconomic factors and lymphoma development, which may help define modifiable risk factors relevant to MCL etiology.

This case report describes a rare transformation of CD5-negative MCL into an EBV-positive pleomorphic variant, highlighting a potential role for EBV in aggressive disease progression and diagnosis.

In a large retrospective series of bilateral lacrimal gland lesions, mantle cell lymphoma was identified as a rare cause (4.4%), highlighting an uncommon extranodal presentation for clinicians.

This preclinical study identifies a novel STAT5B-DCAF13-p53/xCT pathway that suppresses ferroptosis to promote MCL progression, revealing ferroptosis induction as a potential new therapeutic strategy.

A rare case of extranodal composite MCL and classical Hodgkin lymphoma highlights the need for comprehensive pathological workup to identify dual pathologies, which impacts treatment and relapse patterns.

This review consolidates efficacy and toxicity data for FDA-approved CAR-T products in aggressive B-cell lymphomas, including MCL, serving as a practical guide for this established relapsed/refractory treatment.

This case of asymptomatic multiple lymphomatous polyposis in an elderly MCL patient demonstrates that significant GI involvement can be clinically silent, reinforcing the need for routine endoscopic staging.

This single-center retrospective study characterizes the aggressive clinical and pathological features of blastoid MCL, underscoring its diagnostic challenges and the need for novel therapeutic approaches for this high-risk subtype.

This case of lacrimal sac MCL, initially misdiagnosed as a mucocele, highlights a rare extranodal presentation requiring histopathological confirmation for accurate diagnosis in atypical periorbital masses.

Magnetic Resonance Spectroscopy (MRS) can non-invasively detect metabolic changes, like lactate and alanine, offering an early biomarker to predict response or resistance to BTK inhibitors in MCL.

This meta-analysis of 984 R/R MCL patients confirms high CAR-T efficacy (74% CR, 69% 1-year OS), providing robust, pooled outcome data for this heavily pretreated population.

This review summarizes the evolving Japanese MCL treatment landscape, highlighting novel therapies like BTKi, BCL2i, and CAR-T to address resistance in high-risk subsets like TP53-mutated and blastoid.

This indirect comparison shows acalabrutinib has a superior safety profile to ibrutinib in relapsed/refractory MCL with similar efficacy, supporting its preferential use in this setting.

This case report identifies therapy-related acute myeloid leukemia as a serious long-term toxicity after brexucabtagene autoleucel, highlighting the need for post-CAR-T surveillance for secondary malignancies.

This study shows ROR1 is heterogeneously expressed in 44% of MCL tumors, indicating that patient selection will be critical for developing ROR1-targeted therapies like ADCs or CAR-T.

This case of classical MCL rapidly transforming to a blastoid variant with CNS involvement highlights the poor prognosis and failure of BTKi and chemotherapy in this aggressive setting.

A novel 7-gene signature linked to ferroptosis predicts overall survival in MCL, identifying high-risk patients and suggesting potential new therapeutic targets like the MEK inhibitor Trametinib.

In a real-world cohort including MCL, the Hematotox-Score predicted early cytopenias post-CAR-T but not survival, underscoring the need for improved prognostic tools for toxicity management.

This case report details an extremely rare MCL presentation of bilateral hemorrhagic hypopyon, successfully treated with intravitreal rituximab, systemic chemotherapy, and radiation, expanding the differential for unusual ocular findings.

This phase 1 study established the safety and preliminary efficacy of a novel bortezomib, cladribine, and rituximab regimen for older, newly diagnosed mantle cell lymphoma patients.